• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与嵌合跨膜尿激酶受体结合的1型尿激酶 - 纤溶酶原激活物抑制剂复合物的内吞作用

Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.

作者信息

Li H, Kuo A, Kochan J, Strickland D, Kariko K, Barnathan E S, Cines D B

机构信息

Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia 19104.

出版信息

J Biol Chem. 1994 Mar 18;269(11):8153-8.

PMID:7510679
Abstract

The urokinase receptor (uPAR) is linked to plasma membranes through a glycosylphosphatidylinositol (GPI) anchor. It has been posited that the GPI anchor facilitates clearance of uPAR-bound complexes between two chain urokinase (tcuPA) and plasminogen activator inhibitor type 1 (PAI-1) by the alpha 2-macroglobulin receptor (alpha 2MR) which permits re-expression of unoccupied uPA receptors on the cell surface. To test this hypothesis we compared internalization and degradation of 125I-labeled tcuPA-PAI-1 by COS cells expressing either transfected wild-type, GPI-linked uPAR (uPAR/GPI), or a chimeric receptor composed of the extracellular domains of uPAR linked to the transmembrane and cytosolic domains of the alpha chain (p55 subunit) of the interleukin-2 receptor (uPAR/IL-2R alpha). The kinetics of binding, internalization and degradation of tcuPA-PAI-1 by COS cells expressing each form of uPAR were virtually identical. However, internalization of complexes by uPAR/IL-2R alpha was more susceptible to inhibition by recombinant soluble 39-kDa alpha 2MR-associated protein (RAP) which competes for binding of tcuPA-PAI-1 complexes to alpha 2MR (p < 0.001), and the internalization was accompanied by a greater reduction in the number of surface uPAR/IL-2R alpha, than uPAR/GPI (p < 0.05). These studies indicate that the rate of internalization of tcuPA-PAI-1 is governed primarily by the extracellular domains of uPAR, whereas the GPI anchor may facilitate internalization of complexes and re-expression of uPAR when binding sites on alpha 2MR are limiting.

摘要

尿激酶受体(uPAR)通过糖基磷脂酰肌醇(GPI)锚定连接到质膜上。据推测,GPI锚定有助于α2巨球蛋白受体(α2MR)清除uPAR结合的双链尿激酶(tcuPA)与纤溶酶原激活物抑制剂1型(PAI-1)之间的复合物,从而使未占据的uPA受体在细胞表面重新表达。为了验证这一假设,我们比较了表达转染的野生型GPI连接的uPAR(uPAR/GPI)或由uPAR的细胞外结构域与白细胞介素-2受体α链(p55亚基)的跨膜和胞质结构域连接而成的嵌合受体(uPAR/IL-2Rα)的COS细胞对125I标记的tcuPA-PAI-1的内化和降解情况。表达每种形式uPAR的COS细胞对tcuPA-PAI-1的结合、内化和降解动力学几乎相同。然而,uPAR/IL-2Rα对复合物的内化更易受到重组可溶性39 kDaα2MR相关蛋白(RAP)的抑制,RAP可竞争tcuPA-PAI-1复合物与α2MR的结合(p<0.001),并且内化伴随着表面uPAR/IL-2Rα数量的减少比uPAR/GPI更大(p<0.05)。这些研究表明,tcuPA-PAI-1的内化速率主要由uPAR的细胞外结构域决定,而当α2MR上的结合位点有限时,GPI锚定可能促进复合物的内化和uPAR的重新表达。

相似文献

1
Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.与嵌合跨膜尿激酶受体结合的1型尿激酶 - 纤溶酶原激活物抑制剂复合物的内吞作用
J Biol Chem. 1994 Mar 18;269(11):8153-8.
2
Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.纯化的α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白结合尿激酶-纤溶酶原激活物抑制剂1型复合物。α2-巨球蛋白受体介导尿激酶受体结合复合物细胞内降解的证据。
J Biol Chem. 1992 Jul 25;267(21):14543-6.
3
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.参与尿激酶-1型抑制剂复合物和尿激酶原与内吞性α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白结合的区域。尿激酶受体保护尿激酶原不与内吞性受体结合的证据。
J Biol Chem. 1994 Oct 14;269(41):25668-76.
4
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.尿激酶受体通过α-2巨球蛋白受体/低密度脂蛋白受体相关蛋白(Lrp)依赖性内化作用。
J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22. doi: 10.1083/jcb.131.6.1609.
5
Differential regulation of urokinase-type-1 inhibitor complex endocytosis by phorbol esters in different cell lines is associated with differential regulation of alpha 2-macroglobulin receptor and urokinase receptor expression.佛波酯在不同细胞系中对尿激酶-1型抑制剂复合物内吞作用的差异调节与α2-巨球蛋白受体及尿激酶受体表达的差异调节相关。
Mol Cell Endocrinol. 1995 Apr 1;109(2):209-17. doi: 10.1016/0303-7207(95)03504-z.
6
Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.被占据的尿激酶受体(uPAR)与低密度脂蛋白受体相关蛋白的直接结合是uPAR内吞作用和细胞表面尿激酶活性调节所必需的。
Mol Biol Cell. 2001 May;12(5):1467-79. doi: 10.1091/mbc.12.5.1467.
7
Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.单链尿激酶与其受体的相互作用会导致所形成的复合物中出现和消失针对其他细胞表面蛋白的结合表位。
Blood. 1996 Jul 15;88(2):542-51.
8
Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.蛋白酶连接素-1-尿激酶复合物通过一种既需要尿激酶受体又需要α2-巨球蛋白受体的机制被内化并降解。
J Biol Chem. 1994 Jul 8;269(27):17886-92.
9
Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.纤溶酶原激活物抑制剂1衍生肽对单链尿激酶结合、内化及降解的调节作用
J Biol Chem. 1997 Oct 24;272(43):27053-7. doi: 10.1074/jbc.272.43.27053.
10
Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.尿激酶型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物与内吞作用受体α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白及极低密度脂蛋白受体的结合涉及抑制剂中的碱性残基。
Biochem J. 1998 Jan 1;329 ( Pt 1)(Pt 1):55-63. doi: 10.1042/bj3290055.

引用本文的文献

1
Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System.过氧化物酶体增殖物激活受体-γ 配体通过调节纤溶酶原激活系统改变乳腺癌细胞的迁移能力。
J Oncol. 2011;2011:594258. doi: 10.1155/2011/594258. Epub 2011 Oct 29.
2
Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.尿激酶型纤溶酶原激活物(uPA)通过低密度脂蛋白受体相关蛋白(LRP)依赖性激活内皮型一氧化氮合酶诱导肺微血管内皮通透性。
J Biol Chem. 2011 Jul 1;286(26):23044-53. doi: 10.1074/jbc.M110.210195. Epub 2011 May 3.
3
A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.
一种不易断裂的尿激酶型纤溶酶原激活物受体表现出细胞表面清除的失调。
J Biol Chem. 2010 Apr 23;285(17):12595-603. doi: 10.1074/jbc.M109.008581. Epub 2010 Feb 22.
4
Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner.血小板特异性趋化因子血小板因子4通过低密度脂蛋白受体相关蛋白,以核因子κB依赖的方式诱导内皮细胞表达E-选择素。
Blood. 2005 May 1;105(9):3545-51. doi: 10.1182/blood-2004-07-2617. Epub 2004 Dec 9.
5
Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.尿激酶型纤溶酶原激活物受体在极化和非极化的犬肾上皮细胞(Madin-Darby canine kidney epithelial cells)中通过不同机制被内化。
Mol Biol Cell. 1999 Jan;10(1):179-95. doi: 10.1091/mbc.10.1.179.
6
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.尿激酶受体通过α-2巨球蛋白受体/低密度脂蛋白受体相关蛋白(Lrp)依赖性内化作用。
J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22. doi: 10.1083/jcb.131.6.1609.
7
The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae.尿激酶型纤溶酶原激活物受体,一种糖基磷脂酰肌醇连接蛋白,定位于小窝。
J Cell Biol. 1995 Apr;129(2):335-44. doi: 10.1083/jcb.129.2.335.
8
Level of receptor-associated protein moderates cellular susceptibility to pseudomonas exotoxin A.受体相关蛋白水平调节细胞对铜绿假单胞菌外毒素A的敏感性。
Infect Immun. 1995 Aug;63(8):2912-8. doi: 10.1128/iai.63.8.2912-2918.1995.